US Patent #6,756,480 │ WO 2004060386: “Modulators of PTH and PTHrP receptors

and uses for the treatment of bone disorders.”

US Patent #8,992,925 │ WO2007059136: “RANKL antibody-PTH/PTHrP chimeric molecules”

Skeletal unloading inhibits the in vitro differentiation of rat osteoprogenitor cells. Kostenuik PJ, Halloran BP, Morey-Holton ER, and Bikle DD. Am J Physiology 273: E1133-E1139, 1997. PMID: 9435529

 Lack of an effect of spaceflight on bone mass and bone formation in group-housed rats. Wronski TJ, Li M, Shen Y, Miller SC, Bowman BM, Kostenuik PJ, and Halloran BP. J Appl Physiol 85: 279-285, 1998.

PMID: 9655787

Bone and hormonal changes induced by skeletal unloading in the mature male rat. Dehority W, Halloran BP, Bikle DD, Harris J, Curren T, Kostenuik PJ, Wronski TJ, Li M, Bouraoui A, and Morey-Holton ER.  Am J Physiol 276: E62-E69, 1999. PMID: 9886951

 Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I. Kostenuik PJ, Halloran BP, Turner R, Morey-Holton E, Bikle D. J Bone Miner Res 14: 21-31, 1999. PMID: 9893062

RANK is the intrinsic hematopoietic cell surface receptor that control osteoclastogenesis, and regulation of bone mass and calcium metabolism. Li J, Sarosi I, Yan XQ, et al.  Proc Natl Acad Sci USA 97: 1566-1571, 2000. PMID: 10677500

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. Min H, Morony S, Sarosi I, et al. J Exp Med 192: 463-474, 2000. PMID: 10952716

Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Bolon B, Carter C, Daris M, et al. MolTher 3: 197-205, 2001. PMID: 11237676

The effects of osteoprotegerin on the mechanical properties of rat bone. Ross AB, Bateman TA, Kostenuik PJ, Lacey DL, Dunstan CR, Ferguson VL, Simske SJ. J Mat Sci: Materials in Medicine 7: 583-588, 2001. PMID: 15348250

Osteoprotegerin:  A physiological and pharmacological inhibitor of osteoclastic bone resorption. Kostenuik PJ and V. Shalhoub. Curr Pharmaceutical Design 7: 613-635, 2001. PMID: 11375772

OPG and PTH-(1-34) have additive effects on bone mass and mechanical strength in osteopenic ovariectomized rats. Kostenuik PJ, Capparelli C, Morony S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. Endocrinol 142: 4295-4304, 2001. PMID: 11564687

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG):  A pharmacodynamic and pharmacokinetic analysis in rats. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan C, Stouch B, Martin S, Kostenuik PJ. J Bone Miner Res 18: 852-858, 2003. PMID: 12733724

Selective adhesion of osteoblastic cells to different integrin ligands induces osteopontin gene expression. Carvalho RS, Kostenuik PJ, Salih E, Bumann A, Gerstenfeld LC. Matrix Biol 22: 241-249, 2003.

PMID: 12853034

Gene therapy with recombinant osteoprotegerin (OPG) reverses established osteopenia in ovariectomized mice. Kostenuik PJ, Bolon B, Morony S, Carter C, Geng Z, Daris M and Sheng J. Bone 34: 656-664, 2004. PMID: 15050896

Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins. Abrahamsen B, Hjelmborg JVB, Kostenuik PJ, et al. Bone 36: 727-735, 2005. PMID: 15781001

Combined treatment with PTH-(1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Valenta A, Roschger P, Fratzl-Zelman N, Kostenuik PJ, Dunstan CR, Fratzl P, Klaushofer, K. Bone 37: 87-95, 2005. PMID: 15869920

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Kostenuik PJ. Curr Opin Pharmacol 5: 618-625, 2005. PMID: 16188502

The receptor activator of nuclear factor-kB inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Padagas J, Colloton M, Shalhoub V, Kostenuik PJ, et al. Calcif Tissue Int 78: 35-44, 2006. PMID: 16362459

Dkk-1-mediated inhibition of wnt signalling in bone results in osteopenia. Li J, Cattley RC, Sarosi I, Pretorius J, Morony S, Adamu S, Fan W, Kostenuik PJ, Lacey DL, Simonet WS, Bolon B, Shalhoub V, Richards WG. Bone 39: 754-766, 2006. PMID: 16730481

RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis. Kim HKW, Morgan-Bagley S, Kostenuik PJ.  J Bone Miner Res 21: 1946-1954, 2006. PMID: 17002576

The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE.  Osteoporos Int18: 1073-1082, 2007. PMID: 17384898

RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. Jin Q, Cirelli JA, Park CH, Kostenuik PJ, and Giannobile WF. J Periodontol 78: 1300-1308, 2007. PMID: 17608585

Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. Kostenuik PJ, Ferrari S, Pierroz D, et al. J Bone Miner Res22: 1534-1547, 2007.

PMID: 17576164

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. Stolina M, Dwyer D, Zack D, and Kostenuik PJ.  J Immunol 179: 7497-7505, 2007. PMID: 18025194

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodelling in health and disease. Kearns AE, Khosla S, and Kostenuik PJ. Endocr Rev 29: 155-192, 2008.

PMID: 18057140

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. Ominsky MS, Li X, Asuncion F, et al.  J Bone Miner Res 23: 672-682, 2008. PMID: 18433301

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Li X, Ominsky MS, Niu QT, et al. J Bone Miner Res 23:860-869, 2008. PMID: 18269310

Skeletal deterioration induced by RANKL infusion: A model of high-turnover bone disease. Yuan YY, Kostenuik PJ, Morony S, Simionescu DT, Basalyga DM, and Bateman TA. Osteoporosis Int 19: 625-635, 2008. PMID: 18038244

Soluble RANKL induces high bone turnover and decreases bone volume, density and strength in mice. Lloyd SA, Yuan YY, Kostenuik PJ, et al. Calcif Tissue Int 82: 361-372, 2008. PMID: 18465074

Denosumab, a fully human monoclonal antibody versus RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (human/murine) RANKL. Kostenuik PJ, Nguyen H, Warmington K, et al. J Bone Miner Res 24: 182-195, 2009. PMID: 19016581

Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. Li X, Ominsky MS, Warmington KS, et al. J Bone Miner Res 24: 578-588, 2009. PMID: 19049336

Prevention of glucocorticoid-induced bone loss by inhibition of RANKL. Hofbauer LC, Zeitz U, Schoppet M, et al. Arthritis and Rheumatism 60: 1427-1437, 2009. PMID: 19404943

Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Ohishi M, Chiusaroli R, Ominsky M, et al. Am J Pathol 174: 2160-2171, 2009. PMID: 19389927

One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased bone volume, density and strength. Ominsky MS, Stolina M, Li X, Corbin TJ, et al. J Bone Miner Res 24: 1234-1246, 2009. PMID: 19257823

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Li XL, Ominsky MS, Stolina M, et al. Bone 45: 669-676, 2009. PMID: 19539794

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF-alpha or anti-IL-1 therapies. Stolina M, Schett G, Dwyer D, et al. Arthr Res Ther 11: R187 (doi:10.1186/ar2879), 2009.

PMID: 20003323

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. Drake MT, Srinivasan B, Modder UI, et al. J Clin Endocrinol Metab 95: 5056-5062, 2010. PMID: 20631014

Are osteoclasts needed for the anabolic response to PTH? A study of intermittent PTH with denosumab or alendronate in knock-in mice expressing humanized RANKL. Pierroz DD, Bonnet N, Baldock PA, et al. J Biol Chem 285: 28164-28173, 2010. PMID: 20558734

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass and bone strength in aged male rats. Li X, Warmington KS. Niu QT, et al. J Bone Miner Res 25: 2371-2380, 2010.

PMID: 20641040

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density and strength in ovariectomized cynomolgus monkeys. Ominsky MS, Stouch B, Schroeder J, et al. Bone 49: 151-161, 2011. PMID: 21497676

Decreased bone remodeling and porosity were associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Kostenuik PJ, Smith SY, Jolette J, et al.  Bone 49: 162-173, 2011. PMID: 21457806

Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. Li XL, Grisanti M, Wei F, et al. J Bone Miner Res 26: 2610-2621, 2011. PMID: 21773994

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or co-treatment with alendronate in osteopenic ovariectomized rats. Li X, Warmington KS, Niu QT, Grisanti M, et al. Endocrinol 152: 3312-3322, 2011. PMID: 21733832

OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. Sipos W, Zysset P, Kostenuik P, et al. Horm Metab Res 43: 944-9, 2011. PMID: 22161252

Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Shahnazari M, Dwyer D, Chu V, et al. Bone 50: 628-637, 2012. PMID: 22154841

Role of RANK ligand and denosumab, a targeted RANKL inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Clinical Therapeutics 34: 521-536, 2012. PMID: 22440513

Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, et al. Nature Reviews Drug Discovery 11: 401-419, 2012. PMID: 22543469

Osteopetrosis rescue upon RANKL administration to Rankl-/- mice: A new therapy for human RANKL-dependent ARO.  Lo Iacono N, Blair H, Poliani PL, et al. J Bone Miner Res 27: 2501-2510, 2012.

PMID: 22836362
 
The development of denosumab for the treatment of bone loss and cancer-induced bone destruction. Goessl C, Katz L, Dougall WC, Kostenuik PJ, Zoog HB, Braun A, Dansey R, and Wagman RB. Annals NY Acad Sci 1263: 29-40, 2012. PMID: 22831177

On the evolution and contemporary roles of bone remodeling. Kostenuik P. Osteoporosis 4th Edition, Chapter 37: 873-914. Edited by R. Marcus, D. Feldman, D. Dempster, M. Luckey and J. Cauley.  Elsevier, New York, 2013.

Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Chun-Ya H, Kostenuik P, Jurdic P, Ferrari S, Douni E. J Bone Miner Res 29: 1158-1169, 2014. PMID: 24127173

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Stolina M, Dwyer D, Villasenor KS, et al. Bone 67: 305-313, 2014. PMID: 25093263

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Li XL, Niu Q-T, Villasenor KS, et al. Endocrinol 155: 4785-97, 2014. PMID: 25259718

Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. Kostenuik PJ, Smith SY, Samadfam R, et al. J Bone Miner Res 30: 657-669, 2015. PMID: 25369992

Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. Martin A, Xiong J, Koromila T, et al. . Bone 75: 96-104, 2015. PMID: 25701138

Sustained  modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. Ominsky MS, Libanati C, Boyce RW, et al. J Bone Miner Res 30: 1280-1289, 2015. PMID: 25684625

OPG treatment prevents bone loss during lactation but does not affect milk production or maternal calcium metabolism. Ardeshirpour L, Dumitru C, Dann P, Sterpka J, VanHouten J, Kim W, Kostenuik P and Wysolmerski J.  Endocrinology 156: 2762-2773, 2015. PMID: 25961842

OPG-Fc but not zoledronic acid discontinuation reverses ONJ in mice. Molon R, Shimamoto H,

Bezouglaia O, et al. J Bone Miner Res 30: 1627-1640, 2015. PMID: 25727550

Hypocalcemia in patients with metastatic bone disease treated with denosumab. Body JJ, Bone HG, deBoer RH, Stopeck A, van Poznak C, et al.  Eur J Cancer 51: 1812-1821, 2015. PMID: 26093811

Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice. Llyod SA, Morony SE, Ferguson VL, et al. Bone 81: 562-572, 2015. PMID: 26318907.

Serum calcium concentration is maintained when bone resorption is suppressed by osteoprotegerin in young growing male rats. Hohman EE, Hodges JK, Wastney ME, Lachcik PL, Han C-Y, Dwyer D, Peacock M, Kostenuik PJ, and Weaver CM.  Bone 2018;116:162-170. PMID: 30077758

Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. Bougioukli S, Jain A, Sugimoto O, Tinsley BA, Tang AH, Tan MH, Adams DJ, Kostenuik PJ, Lieberman JR. Bone 84:93-103, 2016. PMID: 26723577.

Validation of finite element analysis for quantifying treatment effects of denosumab on vertebral strength in ovariectomized cynomolgus monkeys. Lee DC, Hoffman PF, Varela A, Kostenuik PJ, Ominsky MS, Keaveny TM. J Bone Miner Res  31:1586-1595, 2016.  PMID: 27149403

Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Streicher C, Heyny A, Andrukhova O, Schuler C, Kollmann K, Kantner I, Sexl V, Hofbauer L, Kostenuik PJ, Erben RG. Scientific Reports 2017;7:6460. PMID 28744019.

Fracture Healing physiology and the quest for therapies for delayed healing and nonunion fractures. Kostenuik PJ, Mirza FM. J Orthop Res 2017;35:213-223. PMID: 27743449 

One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, and Hattersley G. Bone 2017;95:143-150. PMID: 27894941

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, and Hattersley G. Osteoporosis Int 2018;29:685-697. PMID: 29260289

Sclerostin-neutralizing antibody enhances bone regeneration around dental implants. Yu SH, Hao J, Fretwurst T, Ominsky M, Liu M, Kostenuik P, Ke HZ, Giannobile WV, and Jin Q. Tissue Engineering Part A 2018;24:1672-1679. PMID: 29921173

Sclerostin and DKK1 inhibition preserves and augments alveolar bone volume and architecture in rats with alveolar bone loss. Liu M, Kurimoto P, Zhang J, Niu QT, Stolina M, Dechow PC, Feng JQ, Hesterman J, Silva MD, Ominsky MS, Richards WG, Ke HZ, and Kostenuik PJ. J Dent Res 97:1031-1038, 2018. PMID:  29617179

Bone resorption is the primary mechanism for transfer of calcium from bone to serum but is not essential for long-term maintenance of serum calcium homeostasis. Hohman EE, Lachcik PL, Han C-Y, Dwyer D, et al. Bone 116:162-170, 2018. PMID:  30077758

Abaloparatide, a novel PTHrP analog for the treatment of postmenopausal osteoporosis, increases bone mass and density at cortical and trabecular sites in an orchiectomized rat model of male osteoporosis. Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Kostenuik P, and Hattersley G.  Bone 2019;120:148-155. PMID: 30343166

Abaloparatide, a selective PTH Receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with closed femoral fractures. Chandler H, Pierce A, Brown J, Ominsky MS, Kostenuik PJ, Beate Lanske, and Hattersley G. J Orthop Res 2019;37:812-820. PMID: 30790359

Immobilization of denosumab on titanium affects osteoclastogenesis of human peripheral blood monocytes. Beck F, Hartmann ES, Kohler MI, Schlussel S, Redeker JI, Schmitt B, Fottner A, Unger M, Michael J, Summer B, Kunzelmann K-H, Scharnweber D, Kostenuik PJ, Mayer-Wagner S. Int J Mol Sci 2019;20:1002. PMID: 30813507

Advances in the management of osteoporosis. Lewiecki EM, Bilezikian J, Giangregorio L, Greenspan L, Khosla S, Kostenuik P, Krohn K, McClung MR, Miller PD, Pacifici R. J Clin Densitom 2019;22:1-19.  PMID: 30366683

​Regional discrepancies in proximal femur and femoral shaft strain following two years of simulated zoledronic acid treatment. Haider I, Kostenuik P, Edwards WB. 22nd International Workshop on Quantitative Musculoskeletal Imaging, 2019. 

​Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects. Yao Y, Kauffmann F, Maekawa S, Sarment L, Sugai JV, Schmiedeler C, Doherty EJ, Holdsworth G, Kostenuik P, Giannobile WV. Scientific Rep, 2020;10:16217. PMID: 33004873

The effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture. Clarke B, Kostenuik P, Wang Y, Tough-DeSapri K. North American Menopause Society Abstract S-8. Menopause 2021;28(12):1438-1476.

​Twelve months antiresorptive treatment in ovariectomized cynomolgus monkeys does not reduce fatigue-life measurements of cortical bone tissue. Haider IT, Sawatsky A, Kostenuik PJ, Boyd SK, Edwards WB. 2021. ASBMR 2021 Annual Meeting.

Abaloparatide effects on cortical volumetric BMD and estimated strength indices of hip subregions by 3D-DXA in women with postmenopausal osteoporosis. Winzenreith R, Humbert L, Boxberger JI, Weiss RJ, Wang Y, and Kostenuik P. J Clin Densitom Jul-Sep;25(3):392-400, 2022. PMID: 35033435

Proximal femur responses to sequential therapy with abaloparatide followed by alendronate in postmenopausal women with osteoporosis by 3D modeling of hip DXA. Winzenreith R, Kostenuik P, Boxberger J, Wang Y, and Humbert L. J Bone Min Res Plus Mar 10;6(4):e10612, 2022. PMID: 35434451

The fatigue life of cortical bone tissue from ovariectomized cynomolgus monkeys is higher in animals treated with alendronate, denosumab, and denosumab after alendronate. Haider IT, Sawatsky A, Kostenuik P, Boyd S, Edwards WB. World Congress on Biomechanics, 2022.

​Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys. Haider IT, Sawatsky A, Zhu Y, Page R, Kostenuik PJ, Boyd S, Edwards WB. Bone 164:116517, 2022. PMID: 35961611

​Abaloparatide increases bone mineral density in regions corresponding to Gruen Zones 1, 2, 6, and 7 in postmenopausal women with osteoporosis. Sheth NP, Winzenrieth R, Humbert L, Kostenuik PJ, Wang Y, Boxberger JI, Bostrom MP. Hip Society Summer Meeting, Santa Monica, CA, 2022.

Dual inhibition of the Wnt inhibitors DKK1 and sclerostin promotes experimental fracture healing and increased the density and strength of non-injured bone: An experimental study in nonhuman primates. Florio M, Kostenuik P, Stolina M, Ascuncion F, Grisanti M, Ke HZ, and Ominsky MS. J Bone Joint Surg 105(15):1145-1155, 2023. PMID: 37159527.

Advances in osteoporosis therapy: Focus on osteoanabolic agents, secondary fracture prevention, and perioperative bone health. Kostenuik P, Binkley N, Anderson P. Curr Osteoporos Rep 21(4):386-400, 2023; PMID : 37289382.

Platelet-rich plasma contains high concentrations of DKK1, a potent inhibitor of Wnt signaling that limits bone regeneration and hair growth. Kostenuik P, Mirza F, Collins M. J Orthopedics & Bone Disorders ​2023 (in press).

Skeletal and osteocyte transcriptomic responses to abaloparatide and teriparatide: A comparative study in estrogen-depleted mice. Lv Z, Zhang J, Liang S, Zhou C, Hu D, Brooks D, Bouxsein M, Lanske B, Kostenuik P, Gori F, Baron R. Submitted, 2023.​​

​Bone and mineral biology is a core competency for PhylonPS, with >30 years of continuous presence in osteoporosis, orthopedics, bone metastasis and related fields.  Dr. Kostenuik has first-hand or consulting-based experience with most therapeutic classes of bone drugs,  including bisphosphonates, estrogens, RANKL inhibitors, PTH receptor agonists, sclerostin antibodies, cathepsin K inhibitors, DKK1 antibodies, wnts, prostaglandins, and BMPs. He is an inventor on patents describing novel long-acting PTH receptor agonists with the potential to treat osteoporosis and other bone loss conditions.  With strong collaborative relationships with top opinion leaders and an extensive publication record in top bone journals, Phylon PS is well positioned to execute or advise on early- and late-stage development programs, medical writing, medical affairs, medical and scientific communications, and investing/partnering/licensing due diligence.

Bone Biology

Some of Dr. Kostenuik's patents and publications in the bone and mineral field: